|Trade Name||Noile-Immune Biotech, Inc.|
|Foundation||April 16, 2015|
|Representative||Hidenobu Ishizaki, President & CEO|
|Headquarters||2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan|
Breakthrough Technology of CAR-T Platform for Solid Tumors
The efficacy of CAR-T cell therapy has demonstrated remarkable success in treating hematologic malignancy. However, this success is not yet extrapolated to solid tumors. To improve the efficacy
of CAR-T cells in solid tumors, we promote the next generation CAR-T platform which is superior to conventional CAR-T cells.
Our breakthrough technology will achieve the desired clinical outcomes.
Partnership with Academic Institutions
We are holding a partnership with the National Cancer Center Japan and Yamaguchi University to improve the accuracy in R&D. Clinical trial-based cooperation with the National Cancer Center Japan that boasts an overwhelming number of cases in the field of cancer treatment will lead to faster clinical trials.
A Team of Globally-Successful Researchers
Our team has extensive experience in cancer immunology and immunotherapy
both in Japan and the US.
We will provide truly effective cancer immunotherapy based on the trends around the world.